ArticleNeuro-oncology2018
Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014.
Article in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 112 citations in OpenAlex.
- Supplementary motor area syndrome in intracranial gliomas is not associated with worse survival.Journal of neuro-oncology · 2026Article
- Construction of an actin cytoskeleton-related gene signature for predicting prognosis and therapeutic response in glioblastoma: based on machine learning.Translational cancer research · 2026Article
- Stimulated Raman Spectroscopy for Intraoperative Glioblastoma Diagnosis-A Complementary Tool to Frozen Section?Cancers · 2026Article
- Article
- Epidemiology and Outcome of Primary Central Nervous System Tumors Treated at King Hussein Cancer Center.Cancers · 2025Article
- Emerging Approaches in Glioblastoma Treatment: Modulating the Extracellular Matrix Through Nanotechnology.Pharmaceutics · 2025Review
- OSMR induces M2 polarization of glioblastoma associated macrophages through JAK/STAT3 signaling pathway.Frontiers in oncology · 2025Article
- Tingling, Numbness, and Underlying Malignancy: A Case Report of Glioblastoma Multiforme.Cureus · 2024Article
- Completely non-invasive prediction of IDH mutation status based on preoperative native CT images.Scientific reports · 2024Article
- Sexual-biased necroinflammation is revealed as a predictor of bevacizumab benefit in glioblastoma.Neuro-oncology · 2024Article
- Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.Journal of neuropathology and experimental neurology · 2024Article
- New insights into targeted therapy of glioblastoma using smart nanoparticles.Cancer cell international · 2024Review
- CD133 significance in glioblastoma development: in silico and in vitro study.European journal of medical research · 2024Article
- BCAS1 defines a heterogeneous cell population in diffuse gliomas.Oncotarget · 2024Article
- B7H3-targeting chimeric antigen receptor modification enhances antitumor effect of Vγ9Vδ2 T cells in glioblastoma.Journal of translational medicine · 2023Article
- Nanoparticle Strategies to Improve the Delivery of Anticancer Drugs across the Blood-Brain Barrier to Treat Brain Tumors.Pharmaceutics · 2023Review
- The intra-tumoral heterogeneity in glioblastoma - a limitation for prognostic value of epigenetic markers?Acta neurochirurgica · 2023Article
- Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry.Annals of hematology · 2023Article
- Assessment and prediction of glioblastoma therapy response: challenges and opportunities.Brain : a journal of neurology · 2023Article
- Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The goal of this study was to provide up-to-date and comprehensive statistics on incidence, survival, and prevalence rates for selected malignant brain and other CNS tumors in adults. Methods: The current study used data from the Central Brain Tumor Registry of the United States, provided by the Centers for Disease Control and Prevention, to examine incidence and data from the Surveillance, Epidemiology, and End Results program to examine survival and prevalence in 16 distinct malignant brain and other CNS histologies in adults (aged 20 y and older at diagnosis) from 2000-2014 overall and by sex, age group, race, and ethnicity. Results: Glioblastoma had the highest incidence (4.40 per 100000) and prevalence (9.23 per 100000). Ependymal tumors had the highest 5- and 10-year relative survivals (87.8% and 84.5%, respectively), while glioblastoma had the lowest 5- and 10-year relative survivals (5.4% and 2.7%, respectively). Females generally had better survival and lower prevalence than males. Younger adults tended to have better survival than older adults, and prevalence varied greatly by age and histology. While survival did not vary significantly by race, white adults had higher prevalence than the other race groups. Hispanics generally had better survival rates and lower prevalence than non-Hispanics. Conclusions: Survival varied greatly by age and ethnicity. Prevalence differed by sex, age, race, and ethnicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.